Ray Wang sees the AI market splitting megacaps into two very different investment stories, and the beaten-down names Wall Street has abandoned may be hiding the more compelling opportunity.
Evercore founder Roger Altman says the stock market is brushing off wars, energy shocks, and rising interest rates as if they barely exist, and he has a specific reason why that resilience holds even…
A 3x leveraged ETF targeting the S&P 500's most volatile stocks sounds like a trader's dream during a bull market, but the mechanics hiding inside its daily reset can quietly destroy returns in ways…
Both Amazon and Microsoft crushed earnings and surged on identical catalysts, but the businesses underneath those matching gains point in very different directions for what comes next.
A former Wall Street trader put half a million XRP on the line to challenge a legendary technical analyst who called XRP bulls the most easily fooled traders he had encountered in 50 years.…
Space generates $500 billion a year yet still settles deals the way it did during the Cold War, and one former astronaut CEO thinks he knows exactly why no one has fixed it yet.
Apple just posted a massive earnings beat and watched its stock fall hard anyway. Before you buy the dip or cut your losses, there is a very specific window forming between now and September…
KLA Corporation just cratered 40% from its highs despite beating earnings five quarters in a row, leaving Wall Street torn between a China-risk nightmare and a structural AI story that one analyst thinks is…
Oracle stock sits 28% in the red while cloud peers celebrate a banner year, and the gap comes down to one brutal question: can a $638 billion backlog and a mountain of AI debt…
SCHD, VYM, and DGRO each solve retirement income differently, and the fund that looks weakest on yield today may leave you with the largest paycheck in 20 years. The gap between them compounds in…
Vertex Pharmaceuticals drops its Q2 2026 results tonight with a $10 billion acquisition just closed, a blockbuster pain drug launch in full swing, and analysts watching one kidney disease drug that could redefine the…
Trump is furious at the oil companies profiting from a war his own administration is fighting, and now a DOJ probe and a possible export ban are putting billions in quarterly earnings directly in…
Palantir has posted triple-digit U.S. commercial growth and a Rule of 40 score that dwarfs NVIDIA, yet the stock sits 30% in the red for the year. Something has to give when Q2 results…
Young adults are now more pessimistic about their finances than Americans over 55, a historic first, and personal finance veteran Beth Kobliner says the numbers explain exactly why so many are skipping stocks and…
Joby Aviation shares have been cut nearly in half over the past year, yet analysts are quietly upgrading their outlooks ahead of a catalyst window packed with international launches, defense contracts, and a pivotal…
